Pharmaceutical

Pharmaceutical

Harbour BioMed Collaborates with Yantai Lannacheng Biotechnology to Develop Radionuclide Drug Conjugates (RDCs)

DRRA1 day ago01 mins

Shots: Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation RDCs Collaboration will combine Harbour’s fully human antibody discovery capabilities via its Harbour Mice platform with Lannacheng’s radiopharmaceutical R&D & commercialization strengths Harbour Mice platform provides fully human mAbs in both conventional & heavy chain-only…

Pharmaceutical

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

DRRA1 day ago01 mins

Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…

Akums signs MoU with Sharda University Agra for pharma research and skill development

DRRA1 day ago01 mins

Akums signs MoU with Sharda University Agra for pharma research and skill development – Express Pharma Home Latest Updates Akums signs MoU with Sharda University Agra for pharma research and skill development …

Indian Immunologicals issues statement on Abhayrab vaccine and Australian advisory

DRRA1 day ago01 mins

Indian Immunologicals issues statement on Abhayrab vaccine and Australian advisory – Express Pharma Home Latest Updates Indian Immunologicals issues statement on Abhayrab vaccine and Australian advisory Source link

Navigating Digitalization, QRM Maturity, and Global Compliance Convergence into 2026

DRRA2 days ago03 mins

PharmTech connected recently with Henrik Johanning, senior vice president, Quality & Strategy, Epista Life Science, to look back at 2025 and ahead into 2026. Johanning details major European regulatory and manufacturing trends transitioning from 2025 into 2026, focusing on the operationalization of modern quality risk management (QRM) and tangible upgrades required for facilities to achieve…

The Top 10 PharmTech Videos of 2025

DRRA2 days ago05 mins

A look back at the top 10 PharmTech videos of 2025 reveals several overarching themes dominating the pharmaceutical industry landscape, primarily centered on advancing complex therapeutic modalities, navigating stringent regulatory environments, and accelerating development through technological integration. A significant focus across these videos was on specialized medicines, including gene therapies using adeno-associated virus (AAV) vectors,…

The End of the ACA Will Hurt All of Us — and Make Healthcare Even More Expensive –

DRRA2 days ago05 mins

Ending the Affordable Care Act wouldn’t fix American healthcare — it would destabilize it. The ACA put a bare floor under coverage, costs, and protections. Removing it would push people back into medical risk markets, raise premiums, shift costs to households and employers, increase emergency care use, and make the entire system more expensive and…

Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

DRRA2 days ago03 mins

New Delhi: Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry, according to Sun Pharma Managing Director Kirti Ganorkar. Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity…

Autonomy Isn’t Binary: How Agentic AI Fits into the Pharma Landscape

DRRA3 days ago05 mins

In September 2025, PharmTech® published the first of what became a three-part series on setting expectations for agentic AI in the pharmaceutical industry, authored by Jason Bryant, senior vice-president of Product Management—AI at ArisGlobal. As 2025 turns to 2026, PharmTech® has interviewed Bryant for a video supplement to these articles, which will again be published…

The Year of the Tariff: Pharmaceutical Supply Chain Reimagined in 2025

DRRA3 days ago05 mins

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, forcing major companies to commit billions to domestic manufacturing to avoid crippling import tariffs (Infographic – article continues below). What was the immediate aftershock, and what major investment pledges followed? The year opened with immediate policy shifts targeting…

Praxis Precision Medicines Reports the US FDA Breakthrough Therapy Designation of Ulixacaltamide for Essential Tremor

New Study Looks At Shopping Malls And What They Mean To People

Mereo BioPharma Reports P-III (ORBIT & COSMIC) Trials Findings on Setrusumab in Osteogenesis Imperfecta

ARS Pharmaceuticals Reports NMPA Approval of neffy 2mg (Epinephrine Nasal Spray) to Treat Type I Allergic Reactions

Lupin signs exclusive agreement with Gan & Lee for Bofanglutide in India

Dr. M’s Women and Children First Podcast #69 Repost – Stephen Porges, Ph.D. – Polyvagal Theory –

Harbour BioMed Collaborates with Yantai Lannacheng Biotechnology to Develop Radionuclide Drug Conjugates (RDCs)

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

Akums signs MoU with Sharda University Agra for pharma research and skill development

Indian Immunologicals issues statement on Abhayrab vaccine and Australian advisory

Navigating Digitalization, QRM Maturity, and Global Compliance Convergence into 2026

The Top 10 PharmTech Videos of 2025

The End of the ACA Will Hurt All of Us — and Make Healthcare Even More Expensive –

Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

Autonomy Isn’t Binary: How Agentic AI Fits into the Pharma Landscape

The Year of the Tariff: Pharmaceutical Supply Chain Reimagined in 2025